Thrombin-antithrombin III complexes in type II diabetes mellitus

Area of Science:

• Endocrinology
• Hematology
• Vascular Medicine

Background:

• Diabetes mellitus is frequently linked to a hypercoagulable state, increasing the risk of thrombotic events.
• Thrombin-antithrombin complex (TAT) is a sensitive marker for activated coagulation.
• Understanding the hemostatic changes in diabetes is crucial for managing vascular complications.

Purpose of the Study:

• To investigate plasma TAT levels in non-insulin-dependent diabetic patients.
• To explore the relationship between TAT levels, vascular complications, and diabetes.
• To assess the impact of diabetes on the activation of the coagulation system, especially during acute vascular occlusions.

Main Methods:

• Plasma samples were collected from a heterogeneous group of non-insulin-dependent diabetic patients.
• Thrombin-antithrombin complex (TAT) levels were determined in plasma.
• TAT levels were compared between diabetic patients (with and without vascular complications) and non-diabetic individuals with vascular disease.

Main Results:

• Elevated plasma TAT levels were observed in the studied group of non-insulin-dependent diabetic patients.
• Increased TAT levels were found in diabetic patients with vascular complications and in non-diabetic patients with vascular disease.
• These findings suggest a link between vascular disease, augmented thrombin activity, and the hemostatic mechanism.

Conclusions:

• Non-insulin-dependent diabetes is associated with increased activation of the coagulation system, as indicated by elevated TAT levels.
• The presence of vascular disease, with or without diabetes, is associated with augmented thrombin activity.
• Diabetes appears to exacerbate the activation of the coagulative system during acute vascular occlusive events.